Antimicrobial agents

Current Opinion in Chemical Biology

Volumn 1, Issue 2, 1997, Pages 169-175

  Bush, Karen ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POSIBACTERIA;

ANTIINFECTIVE AGENT;

CHEMISTRY; DRUG EFFECT; GRAM POSITIVE BACTERIUM; HUMAN; MULTIDRUG RESISTANCE; REVIEW;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE; GRAM-POSITIVE BACTERIA; HUMANS;

EID: 0031197192     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(97)80006-3     Document Type: Article

References (56)

1. Service RF: Antibiotics that resist resistance. Science 1995, 270:724-727.
2. Chopra I, Hodgson J, Metcalf B, Poste G: New approaches to the control of infections caused by antibiotic-resistant bacteria. An industry perspective. J Am Med Assoc 1996, 275:401-403.
3. Chopra I, Hodgson J, Metcalf B, Poste G: The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Antimicrob Agents Chemother 1997, 41:497-503. A biological approach to the development of novel antibacterial agents is presented, emphasizing attempts to circumvent known resistance mechanisms. Methods to identify targets expressed in vivo or targets specifically involved in infection are discussed.
4. Chu DTW, Plattner JJ, Katz L: New directions in antibacterial research. J Med Chem 1996, 39:3853-3874. An excellent perspective is presented from the medicinal chemistry point of view describing target-based antibacterial research. Major groups of compounds directed toward resistant bacteria are presented, with structures, together with possible novel approaches to developing new agents.
5. Stinson SC: Drug firms restock antibacterial arsenal. Chem Eng News 1996:75-100.
6. Bryson HM Spencer CM: Quinupristin-dalfopristin. Drugs 1996, 52:406-415.
7. Millichap J, Ristow TA, Noskin GA, Peterson LR: Selection of Enterococcus faecium strains with stable and unstable resistance to the streptogramin RP59500 using stepwise in vitro exposure. Diagn Microbiol Infect Dis 1996, 25:15-20.
8. Allignet J, Aubert S, Morvan A, El Solh N: Distribution of genes encoding resistance to streptogramin A and related compounds among staphylococci resistant to these antibiotics. Antimicrob Agents Chemother 1996, 40:2523-2528.
9. Aarestrup FM, Ahrens P, Madsen M, Pallesen LV, Poulsen RL, Westh H: Glycopeptide susceptibility among Danish Enterococcus faecium and Enterococcus faecalis isolates of animal and human origin and PCR identification of genes within the VanA cluster. Antimicrob Agents Chemother 1996, 40:1938-1940. A possible source for the VanA cluster of genes found in human clinical enterococcal isolates was identified from a variety of fecal samples from chickens and pigs that were treated with the growth-promoting glycopeptide avoparcin.
10. Noble WC, Virani Z, Cree RG: Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992, 72:195-198.
11. Edmond EB, Wenzel RP, Pasculle AW: Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann Intern Med 1996, 124:329-334.
12. Cooper RDG, Snyder NJ, Zweifel MJ, Staszak MA, Wilkie SC, Nicas TI, Mullen DL, Butler TF, Rodriguez MJ, Huff BE, Thompson RC: Reductive alkytation of glycopeptide antibiotics: synthesis and antibacterial activity. J Antibiot (Tokyo) 1996, 49:575-581.
13. Allen NE, Le Tourneau DL, Hobbs JN: Molecular interactions of a semisynthetic glycopeptide antibiotic with D-Alanyl-D-Alanine and D-Alanyl-D-Lactate residues. Antimicrob Agents Chemother 1997, 41:66-71. Interactions between the novel glycopeptide LY191145 and peptidoglycan dipeptide intermediates are similar to those for vancomycin. The good antibacterial activity of LY191145 against vancomycin-resistant bacteria is thought to be due to strong dimerization of the novel glycopeptide and its more favorable membrane anchoring, leading to increased binding affinities at the bacterial target.
14. 2-Lys-D-Ala-D-Ala. J Am Chem Soc 1996, 18:5874-5880.
15. Allen NE, Hobbs JN, Nicas TI: Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic. Antimicrob Agents Chemother 1996, 40:2356-2362.
16. Nagarajan R: Structure-activity relationships of vancomycin-type glycopeptide antibiotics. J Antibiotics 1993, 46:1181-1195.
17. Fasola E, Spangler SK, Ednie LM, Jacobs MR, Bajaksouzian S, Appelbaum PC: Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1996, 40:2661-2663.
18. Jones RN, Barrett MS, Erwin ME: In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Antimicrob Agents Chemother 1996, 41:488-493.
19. Nicas TI, Mullen DL, Flokowitsch JE, Preston DA, Snyder NJ, Zweifel MJ, Wilkie SC, Rodriguez MJ, Thompson RC, Cooper RDG: Semisynthetic glycopeptide antibiotics derived from LY264B26 active against vancomycin-resistant enterococci. Antimicrob Agents Chemother 1996, 40:2194-2199.
20. Schwalbe RS, McIntosh AC, Qaiyumi S, Johnson JA, Johnson RJ, Furness KM, Holloway WJ, Steele-Moore L: In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother 1996, 40:2416-2419.
21. Slee AM, Wuonola MA, McRipley RJ, Zajac I, Zawanda MJ, Bartholomew PT, Gregory WA, Forbes M: Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother 1987, 31:1791-1797.
22. Brickner SJ, Hutchinson DK, Barbachyn MR, Manninen PR, Ulanowicz DA, Garmon SA, Grega KC, Hendges SK, Toops DS, Ford CW, Zurenko GE: Synthesis of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multi-drug resistant gram-positive bacterial infections. J Med Chem 1996, 39:673-679. Structure-activity relationships and an asymmetric synthetic route leading to the two lead oxazolidinones are discussed.
23. Eustice DC, Feldman PA, Slee AM: Mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis. Biochem Biophys Res Commun 1988, 150:965-971.
24. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC: In vitro activities of new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 1996, 40:1745-1747.
25. Jones RN, Johnson DM, Erwin ME: In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother 1996, 40:720-726.
26. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, Hutchinson DK, Barbachyn MR, Brickner SJ: In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996, 40:839-845.
27. Kaatz GW, Seo SM: In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996, 40:799-801.
28. Mulazimoglu L, Drenning SD, Yu VL: In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996, 40:2428-2430.
29. Ford CW, Hamel JC, Wilson DM, Moerman JK, Stapert D, Yancey RJ, Hutchinson DK, Barbachyn MR, Brickner SJ: In vivo activity of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob Agents Chemother 1996, 40:1508-1513.
30. Testa RT, Petersen PJ, Jacobus NV, Sum P-E, Lee VJ, Tally FP: In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother 1993, 37:2270-2277.
31. Brown BA, Wallace PJ, Onyi G: Activities of the glycylcyclines N,N-dimethylglycylamido-minocycline and N,N-dimethylgrycylamido-6-demethyl-6-deoxytetracycline against Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria. Antimicrob Agents Chemother 1996, 40:874-878.
32. Bergeron J, Ammirati M, Danley D, James L, Norcia M, Retsema J, Strick CA, Su W-G, Sutcliffe J, Wondrack L: Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade tet(M)- and tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996, 40:2226-2228.
33. Agouridas C, Beneditti Y, Bonnefoy A, Collette P, Denis A, Mauvais P, Labbe G, Chantot JF: Ketolides: a new class of macrolide antibacterials. Structural characteristics and biological properties of RU 004. Abstract 14.10, of the 3rd International Conference on the Macrolides, Azalides and Streptogramins, 1996.
34. Jamjian C, Biedenbach DJ, Jones RN: In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004. Antimicrob Agents Chemother 1997, 41:454-459.
35. Chambers HF: In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP2a. Antimicrob Agents Chemother 1995, 39:462-466.
36. Chamberland S, Biais J, Mathias KM, Malouin F, Bond S, Lee VJ: MC-02,331, a new cephalosporin with high affinity for PBP 2a and stability to staphylococcal β-lactamases. Abstract F141, of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996, Sept 15-18, New Orleans.
37. Sundelof JG, Thompson R, White KM, Sasor MW, Cama L, Kropp H: Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1996, 40:795-798.
38. Richter HGF, Angehrn P, Hubschwerlen C, Kania M, Page MGP, Specklin J-L, Winkler FK: Design, synthesis, and evaluation of 2 β-alkenyl penam sulfone acids as inhibitors of β-lactamases. J Med Chem 1996, 39:3712-3722. A series of penam sulfone acids has similar inhibition parameters for class A and class C β-lactamases as the penam sulfone tazobactam, but has different reaction intermediates. Ro 48-1220 enhances the activity of ceftriaxone fourfold to eightfold more effectively than tazobactam against the increasingly important class C cephalosporinase-producing Enterobacteriaceae.
39. Tzouvelekis LS, Gazouli M, Prinarakis EE, Tzelepi E, Legakis NJ: Comparative evaluation of the inhibitory activities of the novel penicillanic acid sulfone Ro 48-1220 against β-lactamases that belong to groups 1, 2b, and 2be. Antimicrob Agents Chemother 1997, 41:475-477.
40. Payne DJ, Bateson JH, Gasson BC, Proctor D, Khushi T, Farmer TH, Tolson DA, Bell D, Skett PW, Marshall AC et al.: Inhibition of metallo-β-lactamases by a series of mercaptoacetic acid thiol ester derivatives. Antimicrob Agents Chemother 1997, 41:135-140. Mercaptoic acid thiol ester analogs were shown to inhibit several subclasses of metallo-β-lactamases. These active-site-directed inhibitors are the first examples of non-β-lactam mechanism-based inhibitors for groups of β-lactamases that have no commercially viable inhibitors.
41. Rasmussen BA, Bush K: Carbapenem-hydrolyzing β-lactamases. Antimicrob Agents Chemother 1997, 41:223-232.
42. Hancock REW: Antibacterial peptides and the outer membranes of gram-negative bacilli. J Med Microbiol 1997, 46:1-3. A review of antibacterial peptides includes their mode of action in Gram-negative bacteria, and the design of novel peptides and their therapeutic potential.
43. Kondejewski LH, Farmer SW, Wishart DS, Hancock REW, Hodges RS: Gramicidin S is active against both gram-positive and gram-negative bacteria. Int J Pept Protein Res 1996, 47:460-466.
44. Fernandez RC, Weiss AA: Susceptibilities of Bordetella pertussis strains to antimicrobial peptides. Antimicrob Agents Chemother 1996, 40:1041-1043.
45. Miyakawa Y, Ratnakar P, Rao AG, Costello ML, Mathieu-Costello O, Lehrer RI, Catanzaro A: In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis. Infect Immun 1996, 64:926-932.
46. Hirakura Y, Alvarez-Bravo J, Kurata S-I, Natori S, Kirino Y: Selective interaction of synthetic antimicrobial peptides derived from sapecin B with lipid bilayers. J Biochem 1996, 120:1130-1140.
47. Falla TJ, Karunaratne DN, Hancock REW: Mode of action of the antimicrobial peptide indolicidin. J Biol Chem 1996, 271:19298-19303.
48. Mason DJ, Dybowski R, Larrick JW, Gant VA: Antimicrobial action of rabbit leukocyte CAP18106-137. Antimicrob Agents Chemother 1997, 41:624-629.
49. Gough M, Hancock REW, Kelly NM: Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 1996, 64:4922-4927. Two small cationic peptides with antiendotoxin activity due to binding to lipopolysaccharide demonstrated antibacterial activity against Pseudomonas aeruginosa both in vitro and in vivo in neutropenic mice.
50. Lin Y, Leach WJ, Ammons WS: Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein and cefamandole in treatment of rabbit Gram-negative sepsis. Antimicrob Agents Chemother 1996, 40:65-69.
51. Onishi HR, Pelak BA, Gerckens LS, Silver LL, Kahan FM, Chen M-H, Patchett AA, Galloway SM, Hyland SA, Anderson MS, Raetz CRH: Antibacterial agents that inhibit lipid A biosynthesis. Science 1996, 274:980-989. Lipid A biosynthesis represents an unexploited target for antibacterial research. The most active deactylase inhibitor described was bactericidal and cured mice of a lethal E. coli infection, but was inactive against infections caused by other Enterobacteriaceae, suggesting high bacterial specificity for these inhibitors.
52. Thomson KS, Chartrand SA, Sanders CC, Block SL: Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 1997, 41:478-480.
53. Cormican MG, Jones RN: Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrob Agents Chemother 1997, 41:204-211.
54. Hughes J, Mellows G: On the mode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus. Antimicrob Agents Chemother 1989, 33:156-163.
55. Udo EE, Jacob LE, Mokadas EM: Conjugative transfer of high-level mupirocin resistance from Staphylococcus haemolyticus to other staphylococci. Antimicrob Agents Chemother 1997, 41:693-695.
56. Broom NJP, Cassels R, Cheng H-Y, Elder JS, Hannan PCT, Masson N, O'Hanlon PJ, Pope A, Wilson JM: The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity. J Med Chem 1996, 39:3596-3600. Oxazole isosteres of pseudomonic acid were synthesized with a second mode of action separate from that of isoleucyl-tRNA synthetase inhibition. Both in vitro and in vivo activity of the isosteres were demonstrated.